• Citer

CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: A retrospective substudy of the HERA trial (BIG 1-01)

par Pestalozzi, Bernhard Cornelius;Holmes, Eileen;de Azambuja, Evandro ;Metzger-Filho, Otto;Hogge, Laurence;Scullion, Matt;Lang, Istvan;Wardley, Andrew;Lichinitser, Mikhail;Sanchez, Roberto I Lopez;Müller, Volkmar;Dodwell, David;Gelber, Richard;Piccart-Gebhart, Martine ;Cameron, David A
Référence Lancet oncology, 14, 3, page (244-248)
Publication Publié, 2013-03

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: A retrospective substudy of the HERA trial (BIG 1-01)
Auteur:	Pestalozzi, Bernhard Cornelius; Holmes, Eileen; de Azambuja, Evandro; Metzger-Filho, Otto; Hogge, Laurence; Scullion, Matt; Lang, Istvan; Wardley, Andrew; Lichinitser, Mikhail; Sanchez, Roberto I Lopez; Müller, Volkmar; Dodwell, David; Gelber, Richard; Piccart-Gebhart, Martine; Cameron, David A
Informations sur la publication:	Lancet oncology, 14, 3, page (244-248)
Statut de publication:	Publié, 2013-03
Sujet CREF:	Cancérologie
MeSH keywords:	Adult
	Aged
	Antibodies, Monoclonal, Humanized -- administration & dosage -- adverse effects
	Antineoplastic Agents -- administration & dosage -- adverse effects
	Breast Neoplasms -- drug therapy -- genetics -- mortality -- pathology
	Central Nervous System Neoplasms -- chemically induced -- secondary
	Chemotherapy, Adjuvant -- adverse effects
	Clinical Trials as Topic
	Disease-Free Survival
	Female
	Humans
	Middle Aged
	Neoplasm Staging
	Receptor, ErbB-2 -- genetics
	Recurrence
	Retrospective Studies
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:1470-2045
	info:doi/10.1016/S1470-2045(13)70017-2
	info:pii/S1470204513700172
	info:scp/84875236228
	info:pmid/23414588